Emerging ceftazidime-avibactam resistance against carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Lebanon

Authors

  • Ghena M Sobh Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon
  • Abdul Karim El Karaaoui MD, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon
  • Mira El Chaar PhD, Faculty of Health Sciences, University of Balamand, Beirut, Lebanon
  • George F Araj PhD, D(ABMM), FAAM, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

DOI:

https://doi.org/10.3823/858

Keywords:

antimicrobial resistance, ceftazidime avibactam, carbapenem resistance, CR E. coli, CR K. pneumoniae, Lebanon

Abstract

Introduction: Ceftazidime-avibactam (CZA) has been introduced as a novel drug to essentially combat the rising trends of carbapenem resistant Enterobacteriaceae. In the absence of in vitro data about the activity of this drug against carbapenem resistant (CR) Escherichia coli and Klebsiella pneumoniae in Lebanon, this study was warranted.     

 

Methodology: A total of 150 isolates, identified using the MALDI-TOF,  encompassing 50 CR E. coli, 60 CR K. pneumoniae, and 10 isolates each of extended-spectrum Beta-lactamases (ESBLs), and non-CR multidrug-resistant (MDR) of each species were analyzed.  The minimum inhibitory concentration (MIC) for CZA was determined by the E-test (Liofilchem, Roseto degli Abruzzi, Italy). In addition, the disk diffusion (DD) test was used to determine the activity of CZA and of the antimicrobials routinely used to test for such pathogens.

 

Results:  The CZA activity against the 50 CR E. coli showed an MIC50 ≥ 256 μg/mL, an MIC90 ≥ 256 μg/mL, and an MIC range of 0.023 to ≥ 256 μg/mL, reflecting a susceptibility of 40 %. As For the 60 CR K. pneumoniae isolates, the MIC50 was ≥ 256 μg/mL, MIC90 ≥ 256 μg/mL, and the MIC range was 0.094 to ≥ 256 μg/mL, reflecting a susceptibility of 35%. However, uniform CZA susceptibility (100%) was detected against ESBL and MDR isolates of both species, being comparable or higher to the routinely used antimicrobials.

 

 

Conclusion: Although CZA was recently introduced into this country, it was surprising to note this humble susceptibility of CZA against CR E. coli and CR K. pneumoniae. To explain such findings, it is worth pursuing investigations related to antimicrobial utilization in clinical practice and antimicrobial stewardship. Moreover, genotypic determination is needed to be revealed to help explain the observed phenotypic resistance

 

 

Author Biographies

Ghena M Sobh, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

 

Abdul Karim El Karaaoui, MD, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

MD, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

 

Mira El Chaar, PhD, Faculty of Health Sciences, University of Balamand, Beirut, Lebanon

PhD, Faculty of Health Sciences, University of Balamand, Beirut, Lebanon

George F Araj, PhD, D(ABMM), FAAM, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

PhD, D(ABMM), FAAM, Department of Pathology and Laboratory Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

 

References

Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis2019;19(1):4-6. doi: 10.1016/S1473-3099(18)30648-0. Epub 2018 Nov 5. PMID: 30409682.

Kaye KS, Pogue JM. Infections caused by resistant Gram-negative bacteria: Epidemiology and Management. Pharmacotherapy 2015;35 (10): 949-962. doi: 10.1002/phar.1636. PMID: 26497481.

Zasowski EJ, Rybak JM, Rybak MJ. The β-Lactams strike back: Ceftazidime-avibactam. Pharmacotherapy2015;35(8):755-770. doi: 10.1002/phar.1622. PMID: 26289307; PMCID: PMC4545577.

Torres A, Rank D, Melnick D, Rekeda L, Chen X, Riccobene T et al. Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): Analyses per US FDA-specified end points. Open Forum Infect Dis 2019 Apr 25;6 (4):ofz149. doi: 10.1093/ofid/ofz149. PMID: 31041348; PMCID: PMC6483139.

Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 2013;73(2):159-177. doi: 10.1007/s40265-013-0013-7. PMID: 23371303.

Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist 2020;22:18-27. doi: 10.1016/j.jgar.2019.12.009. Epub 2019 Dec 19. PMID: 31863899.

Araj GF, Avedissian AZ, Itani LY, Obeid JA. Antimicrobial agents active against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates in Lebanon. J Infect Dev Ctries 2018;12(3):164-170. doi: 10.3855/jidc.9729. PMID: 31829991.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug- resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. ClinMicrobiol Infect 2012;18: 268-281.

Araj GF, Ibrahim GY. Tigecycline in vitro activity against commonly encountered multidrug-resistant Gram- negative pathogens in a Middle Eastern country. DiagnMicrobiol Infect Dis2008;62: 411- 415.

Flamm RK, Nichols WW, Sader HS, Farrell DJ, Jones RN. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalized patients, including ventilated patients. Int J Antimicrob Agents 2016;47(3):235-42. doi:

Gonzalez MD, McMullen AR, Wallace MA, Crotty MP, Ritchie DJ, Burnham CA. Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of β-lactam-resistant Gram-negative bacteria. Ann Lab Med 2017;37(2):174-176. doi: 10.3343/alm.2017.37.2.174. PMID: 28029009; PMCID: PMC5204000.

Hachem R, Reitzel R, Rolston K, Chaftari AM, Raad I. Antimicrobial Activities of ceftazidime-avibactam and comparator agents against clinical bacteria isolated from patients with cancer. Antimicrob Agents Chemother 2017;61(4):e02106-16. doi: 10.1128/AAC.02106-16. PMID: 28115350; PMCID: PMC5365661.

Yasir M, Ajlan AM, Shakil S, Jiman-Fatani AA, Almasaudi SB, Farman Met al. Molecular characterization, antimicrobial resistance and clinico-bioinformatics approaches to address the problem of extended-spectrum β-lactamase-producing Escherichia coli in western Saudi Arabia. Sci Rep2018;8(1):14847. doi: 10.1038/s41598-018-33093-8. PMID: 30287889; PMCID: PMC6172265.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de JongeBL et al. Assessment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM global surveillance study, 2012 to 2014. Antimicrob Agents Chemother2016;60(8):4677-83. doi: 10.1128/AAC.02841-15. PMID: 27216054; PMCID: PMC4958227.

Rossolini GM, Stone GG. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017). Int J Antimicrob Agents 2020;56(3):106111. doi: 10.1016/j.ijantimicag.2020.106111. Epub 2020 Jul 25. PMID: 32721602.

Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu Det al. China antimicrobial surveillance network (CHINET) study group. Results from the China antimicrobial surveillance network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonasaeruginosa. Antimicrob Agents Chemother2019;63(4):e02431-18. doi: 10.1128/AAC.02431-18. PMID: 30617091; PMCID: PMC6437533.

Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y et al. Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem resistant Enterobacteriaceae. Antimicrob Agents Chemother 2019;63(3):e02048-18. doi: 10.1128/AAC.02048-18. PMID: 30617090;

PMCID: PMC6395938.

Rossi F, Cury AP, Franco MRG, Testa R, Nichols WW. The in vitro activity of ceftazidime-avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil. Braz J Infect Dis 2017;21(5):569-573. doi: 10.1016/j.bjid.2017.03.008. Epub 2017 Apr 20. PMID: 28435011.

Castanheira M, Mendes RE, Jones RN, Sader HS. Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: Activity of ceftazidime-avibactam tested against β-lactamase-producing isolates. Antimicrob Agents Chemother22;60(8):4770-7. doi: 10.1128/AAC.00540-16. PMID: 27216075; PMCID: PMC4958231.

Zhang Y, Kashikar A, Brown CA, Denys G, Bush K. Unusual Escherichiacoli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam. Antimicrob Agents Chemother 2017;61(8):e00389-17. doi: 10.1128/AAC.00389-17. PMID: 28559260; PMCID: PMC5527577.

Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonasaeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother 2017;61(11):e01045-17. doi: 10.1128/AAC.01045-17. PMID: 28827415; PMCID: PMC5655084.

Zou C, Wei J, Shan B, Chen X, Wang D, Niu S. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant Enterobacteriaceae isolates collected from three secondary hospitals in southwest China between 2018 and 2019. Infect Drug Resist 2020;13:3563-3568. doi: 10.2147/IDR.S273989. PMID: 33116675; PMCID: PMC7567573.

Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona Let al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichiacoli, Klebsiellapneumoniae, and Pseudomonasaeruginosa. Int J Infect Dis 2017;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10. PMID: 28610832.

Sonnevend Ã, Ghazawi A, Darwish D, Barathan G, Hashmey R, Ashraf T et al. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Int J Infect Dis 2020;99:253-259. doi: 10.1016/j.ijid.2020.07.050. Epub 2020 Jul 29. PMID: 32738488.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother 2018;73(10):2782-2788. doi: 10.1093/jac/dky266. PMID: 30010894.

Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA et al. High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. Clin Infect Dis2016;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16. PMID: 27313265.

Schillaci D, Spanò V, Parrino B, Carbone A, Montalbano A, Barraja P et al. Pharmaceutical approaches to target antibiotic resistance mechanisms. J Med Chem 2017;60(20):8268-8297. doi: 10.1021/acs.jmedchem.7b00215. Epub 2017 Jun 20. PMID: 28594170.

Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpCcephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. Int J Antimicrob Agents 2018;52(5):697-701. doi: 10.1016/j.ijantimicag.2018.07.027. Epub 2018 Aug 3. PMID: 30081137.

Baroud M, Dandache I, Araj GF, Wakim R, Kanj S, Kanafani Z et al. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. Int J Antimicrob Agents. 2013 Jan;41(1):75-9. doi: 10.1016/j.ijantimicag.2012.08.010. Epub 2012 Nov 9. PMID: 23142087.

Kissoyan KA, Araj GF, Matar GM. Prevalence of carbapenem resistance genes and corresponding MIC90 in Enterobacteriaceae at a tertiary care center in Lebanon. J Infect Dev Ctries2018;12(2.1):9S. doi: 10.3855/jidc.10097. PMID: 31804984

Dagher C, Salloum T, Alousi S, Arabaghian H, Araj GF, Tokajian S. Molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon. PLoS One 2018;13(9):e0203323. doi: 10.1371/journal.pone.0203323. PMID: 30188911; PMCID: PMC6126819.

Downloads

Published

2021-07-25

Issue

Vol. 11 No. 2 (2021)

Section

Articles

License

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Articles are published Under License of Creative Commons Attribution 3.0 License ©

 

Copyright policies & self-archiving

This is our Copyright Policy. We are a RoMEO green journal.

Author's Pre-print: green tick  author can archive pre-print (ie pre-refereeing)
Author's Post-print: green tick  author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: green tick  author can archive publisher's version/PDF